Search clinical trials for: cetuximab (Erbitux)

Total 3109 results

Hoffmann-La Roche

Completed

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Italy, Korea, Republic of, Australia, Canada, Czechia, Spain, United Kingdom, France, Germany, Hungary, Turkey, Netherlands
Western Regional Medical Center

Withdrawn

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Lymphoma | Hodgkin's Lymphoma | Non-hodgkin's Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

Leukemia | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Allogeneic Marrow Transplant

United States
M.D. Anderson Cancer Center
Biogen

Completed

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Leukemia

United States
Hamamatsu University

Unknown

Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection

Gastritis | Helicobacter Infections | Gastric Ulcer | Duodenal Ulcer

Japan
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
ImmunityBio, Inc.

Recruiting

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Non Hodgkin's Lymphoma Refractory/Relapsed

United States
Sanofi

Recruiting

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (MAYARI)

Thrombotic Thrombocytopenic Purpura

Italy, Belgium, France, Greece, United States, Austria, Canada, Czechia, Germany, Japan, Netherlands, Spain, United Kingdom
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Pharmatech

Completed

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Lymphoma

United States
Medical University of Vienna

Completed

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Rheumatoid Arthritis

Austria, Czechia, Russian Federation, Switzerland
Brown University
The Miriam Hospital; Rhode Island Hospital; Spectrum Pharmaceuticals, Inc

Completed

Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma (BRiM)

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Lymphoma, B-Cell, Marginal Zone | Waldenstrom Macroglobulinemia | Lymphoma, Small-Cell

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Esophageal Cancer

United States
GlaxoSmithKline

Completed

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin

United States, France, United Kingdom
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, Belgium, France, Brazil, Ireland, Czechia, Romania, Portugal, Georgia, Argentina, Poland, Puerto Rico, Austria, Switzerland
Hansa Biopharma AB

Recruiting

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)

Kidney Transplantation in Highly Sensitized Patients

United States
Hospital for Special Surgery, New York
GlaxoSmithKline

Recruiting

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis

United States
Massachusetts General Hospital

Recruiting

The Role of Estrogen in the Neurobiology of Eating Disorders

Eating Disorders | Hypoestrogenemia

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, Australia, Spain, France
University of Giessen
Novartis; Astellas Pharma US, Inc.; German Cancer Research Center; Heidelberg University

Completed

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

Kidney Transplantation | Immunology | Virus | Living Donors | Rituximab (RTx)

Germany
University of Washington
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma (TREC)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma

United States
Hospital de Clinicas de Porto Alegre
Aché Laboratórios Farmacêuticos Ltda

Completed

Helicobacter Eradication Relief of Dyspeptic Symptoms (HEROES-12)

Functional Dyspepsia

Brazil
University of Miami

Terminated

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma

United States
Hoffmann-La Roche
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

Rheumatoid Arthritis

Belgium, France, Germany, Norway, United Kingdom, United States, Ireland, Canada, Israel, Netherlands, Italy
Georgetown University
Celgene Corporation; Cephalon

Completed

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (Phase I BLR)

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia

United States
Eli Lilly and Company

Completed

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Colorectal Cancer | Metastatic Melanoma | Advanced Cancer | Metastatic Non-small Cell Lung Cancer

United States, Japan, Australia, France
Peking University
Zhejiang University; Liaoning Tumor Hospital & Institute

Active, not recruiting

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

mCRC

China
Hospices Civils de Lyon

Completed

GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis (GRECCAR8)

Rectal Adenocarcinoma

France
Peking Union Medical College Hospital

Recruiting

Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

Primary Vitreoretinal Lymphoma

China
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (VEGA)

Lymphoma, Mantle-Cell

Taiwan, Thailand, Malaysia, India, Puerto Rico, Spain, Turkey, Czechia, Brazil, Greece, Poland, Sweden, Romania
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Completed

Combination Chemotherapy in Treating Women With Breast Cancer

Breast Cancer

United States
University of Miami
AstraZeneca

Terminated

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Small Lymphocytic Leukemia

United States
Washington University School of Medicine

Completed

Assessment and Management of Chronic Dyspepsia in Eastern Uganda

Dyspepsia | Helicobacter Pylori Infection

United States
Hoffmann-La Roche

Terminated

A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Diffuse Large B-Cell Lymphoma

Romania
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Lymphoma | Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
Bayer

Completed

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Non-Myeloablative Allogeneic Stem Cell Transplantation

Lymphoma

United States
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Canada, Germany
Fox Chase Cancer Center
Genentech, Inc.

Withdrawn

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Maple Leaf Research

Recruiting

Drug-Drug Interaction Study in Trans Women Living With HIV (T-DDI)

Hiv | Transgenderism

Canada
Jianfeng Zhou
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma
Porteus, Matthew, MD

Recruiting

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Fanconi Anemia

United States
Peking Union Medical College Hospital

Recruiting

Different Immunosuppressive Treatment in iMN

Idiopathic Membranous Nephropathy

China
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States
Beijing Tiantan Hospital

Recruiting

Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)

MRI | Multiple Sclerosis | NMO Spectrum Disorder

China
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Spain, Czechia, Taiwan, Italy, Japan, New Zealand, Poland, Hungary, United States, United Kingdom, Australia, Romania, Portugal, Korea, Republic of, Russian Federation, Austria, Brazil, Bulgaria, France, Ireland

Search clinical trials for: cetuximab (Erbitux)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations